



Innovation

*Tradition
meets*

Bavaria

BIOTECH IN BAVARIA
TRANSFORMATION IN PROGRESS

Brandnew facts and figures	Page 2	Spotlight Regensburg	Page 6
Selected recent headlines	Page 3	Technologies you must have seen	Page 7
BioEntrepreneurs in Bavaria	Page 4	Events and Contact	Page 8
Bavaria worldwide	Page 5		

Dear reader,

The Bavarian Biotech Report 2018/19 in which we provide a detailed insight into the Bavarian BioPharma ecosystem has just been published. With emphasis on the scientific landscape as well as the more than 360 companies and a workforce of 34,000, developing drugs and diagnostics – or delivering *enabling technologies* to find best-in-class compounds – this Report also contains a comprehensive list and short profiles of almost all companies. In a nutshell we present here the key figures related to 'medical biotechnology' (see below).

Find more details, statements and interviews within the [Bavarian Biotech Report 2018/19](#)



Short Facts: Focus on Biotech Numbers in Bavaria





237 Biotech Companies



14,800 Employees

229 Projects in Drug Pipeline



apceth acquired by Hitachi

Hitachi Chemical acquired Munich-based apceth Biopharma GmbH, a leading provider of cell and gene therapies, for EUR 75 million. The acquisition was completed in April 2019. apceth was founded in 2007 and is located in Munich-Großhadern and Ottobrunn near Munich. As a pioneer in cell and gene therapy, the company has developed into one of Europe's leading contract development and contract manufacturing (CDMO) companies for advanced therapies (ATMP).

www.apceth.com



MAB Discovery acquired by BioNTech

BioNTech, based in Mainz, Germany, acquired MAB Discovery's operational antibody production unit and thereby uses the proprietary technologies of the Munich-based biotech company to generate therapeutic monoclonal antibodies. While BioNTech acquired all of MAB Discovery's assets, employees and proprietary know-how for mAb generation, MAB Discovery retains ownership and all rights to its proprietary preclinical development pipeline and existing service agreements with third parties. The acquisition is the result of a successful five-year collaboration between the companies. BioNTech is the largest unlisted biopharmaceutical company in Europe.


www.biontech.de



Networking at the German Biotechnology Days 2019 in Würzburg

The German Biotechnology Days (DBT) 2019 took successfully place on 8 and 9 April in Würzburg. The largest event of the German biotech industry brought together nearly 800 attendees to present and discuss the latest trends and developments in the field of biotechnology. The conference is an annual 2-day event which represents a leading networking platform where all stakeholders active in the German biotechnology sector exchange their views and experience.

www.biotechnologietage.de/en



Bavarian joint stand at DBT 2019, Würzburg
© Bio Deutschland / Andreas Grasser

Roche Biotech Day – a look into the future

At the first edition of the Roche Biotech Day, renowned experts provided information on current trends for the future of biotechnology. The spectrum ranged from synthetic biology, new molecule formats and AI to personalized vaccines and individual genome analysis. Around 100 scientists from Munich universities, research institutes and biotech companies met with around 150 Roche scientists on April 2 on the Penzberg Roche Campus. The event was realized in cooperation with Bio^M.

[Read more...](#)



Prof. Horst Domdey, Managing Director Bio^M, opens Roche Biotech Day 2019 in Penzberg. © Roche

Why Bavaria?

Excellent Infrastructure

Excellent infrastructure and promotion for SMEs

- Biotech cluster management: Bio^M is identifying and connecting the appropriate partners from science, industry, medicine and finance
- Matchmaking, networking & partnering events
- Special promotion programs for small and medium-sized enterprises by the State of Bavaria

Life Science Research

Largest research community in Germany

- Max Planck Institutes
- Fraunhofer Institutes
- Helmholtz Zentrum München
- Excellent Universities and their hospitals



Great public funding opportunities for start-ups

- Bavaria: BFS, BayTOU,
- BMBF: GO-Bio, KMU innovativ
- BMWi: EXIST, HTGF, ZIM;
- EU: Horizon 2020, EIT Health, IMI

Abundance of world-class, well funded biomedical research with focus on:

- Digitization
- Precision medicine
- Immune oncology
- Biomarker diagnostics

Public Funding Opportunities

The right Focus

A Bavarian success story: Smart4Diagnostics

The Bavarian start-up Smart4Diagnostics takes one step after another towards success. It is the winner of EIT Health WildCard, TECHFEST Munich and Pioneer Award, finalist at the WHO World Health Summit and part of the Startup Creasphere



The Team of Smart4Diagnostics winning the EIT Health Wild Card competition. © Smart4Diagnostics

Digital Health Accelerator Batch One by Plug and Play together with Roche. The start-up values Munich and the region around Erlangen as extremely innovative areas in the medtech field. Smart4Diagnostics offers digital solutions for transporting human blood samples from collection to laboratory analysis by monitoring all relevant quality factors in real time.

www.smart4diagnostics.com

New biotech companies in Bavaria in 2018/19

Company	Category	Location
Adivo	Therapeutics	Munich
Analife	Data Science	Würzburg
Smart4Diagnostics	Devices	Munich
EpiQMAx	Diagnostics	Munich
Gotham therapeutics	Therapeutics	Munich
Invitrocue	Diagnostics	Munich
Ipsen	Therapeutics	Munich
ISAR Bioscience	Biotech Translational R&D	Munich
LDC Biologics	Therapeutics	Munich
NCD Company	Services	Munich
Octamer	Diagnostics	Munich
PhenYTE UG	Nutrition	Regensburg
Telexos	Diagnostics	Munich

- 10 biotechnology companies founded
- 3 are spin-offs of scientific research institutions
- 3 companies have been relocated

March: BIO-Europe Spring 2019 in Vienna

The Bavarian joint booth at BIO-Europe Spring from 25 to 27 March 2019 in Vienna was organized by Bayern International for the first time in cooperation with Bio^M for this partnering conference. The six Bavarian exhibitors - Aurigon, Coriolis Pharma, EpiQMax, Medizone, NDA, PAN Biotech - were very pleased with the response and especially with the quality of the discussions at the booth and in the partnering. BIO-Europe Spring takes place annually in changing cities and is one of Europe's largest partnering conference, serving the global biotech industry. www.ebdgroup.com



Bavarian joint booth at the BIO-Europe Spring 2019 in Vienna © Bio^M

April: Annual CEBR Meeting

The CEBR Annual Meeting successfully took place on April 4/5 in Athens, Greece. The board was newly elected with now nine people on the CEBR board. Stephanie Wehnelt (Bio^M) will again take over the presidency.

www.cebr.net



German Life Science Accelerator and Bio^M at Boston Biotechnology Summit

Boston Biotechnology Summit: Bridge To Collaboration at Wistar Institute in Philadelphia, PA, will take place on **June 2nd** (just before the start of BIO International Convention). Annika Pierson, GALS COO, will moderate a panel on international collaboration in biotech. Participants will be esteemed members of the European and U.S. life sciences community. Prof. **Horst Domdey**, Managing Director of Bio^M Biotech Cluster Development GmbH, will participate in the discussion.

www.bostonbiotechnologysummit.com



Get in touch with the Bavarian biotech community




BioPark Regensburg

BioPark Regensburg is celebrating its 20th birthday. The BioPark Regensburg GmbH is the management and administrative headquarters of the biotechnology research cluster known as BioRegio Regensburg in East Bavaria. Located strategically at the northernmost point of the Danube, in the Austrian-Czech-German triangle, the area is regarded as the gateway to the East of the extended European Union. Currently more than 50 companies with almost 4,000 employees are active in the field of life sciences in BioRegio Regensburg, a good ten times more than 20 years ago.



Dr. Thomas Diefenthal
CEO, BioPark
Regensburg GmbH



www.biopark-regensburg.de/en

Health Accelerator – BioPark jumping for innovation

“BioPark-Jump“ at BioPark Regensburg has started with its first project team in the field of trauma surgery. The Accelerator is intended to provide consultancy in particular to regional innovations and startups in the Regensburg Bioregion. “With BioPark Jump future creative applications and ideas will not get lost in the region”, Dr. Ilja Hagen Project Manager for Healthcare is happy to say. [Read more...](#)

Dr. Philipp Beckhove



Philipp Beckhove, M.D., Ph.D., is the Director of Regensburg Center of Interventional Immunology (RCI) at University of Regensburg, Germany. As tumor immunologist, Philipp's scientific work focuses on translating basic immunological research into new therapies for oncology. Prior to joining RCI in 2015, Philipp headed the Division of Translational Immunology at the German Cancer Research Center in Heidelberg, Germany from 2011-2015. In 2016 he co-founded iOmX Therapeutics which gained a huge Series-A financing round of more than € 40m. www.rcii.de/en

What's the most exciting development in your research field right now, and what decisive breakthroughs do you expect in the next 10 years?

The growing understanding of the extensive role played by immune cells in keeping the body healthy – not only with respect to fighting pathogens, but also to maintaining tissue function. Identifying and understanding the diverse communication lines between immune cells and tumor cells is particularly exciting, as this will dictate how successfully we can treat cancer in the future.

All Company Profiles of the Bavarian Biotech Cluster in our annual report:



Nanon



Nanon Technologies is a leading provider of automated patch clamp (APC) electrophysiology systems with throughput capabilities ranging from a single cell up to fully automated high throughput screening (HTS) instruments recording from 384 cells simultaneously. Founded in 2002 as a spin-off from the University of Munich, Center for Nanoscience (CeNS), Nanon has expanded its product range over the years to include in vitro systems for membrane pump and transporter recordings, bilayers, and contractility measurements (impedance) from beating monolayers of cells, e.g. induced pluripotent stem cell-derived cardiac myocytes (iPSC-CMs), and confluency measurements of, e.g. hepatocytes for hepatotox screening using impedance. www.nanon.de/en

ChromoTek



ChromoTek is pioneer and leading supplier of innovative tools, reagents and assays based on alpaka single domain antibodies (also known as nanobodies). Our products simplify, accelerate and improve research applications in biochemistry, proteomics, microscopy and live cell imaging. Nanobodies provide unique properties such as small size, conformational epitope coverage, nano- to picomolar binding affinity and exceptional chemical protein stability. The latest premium tool is the Spot-Tag and Spot-Tag nanobody system - the first peptide-tag/nanobody system for demanding capture and detection applications including high resolution imaging. www.chromotek.com



Dr. Marion Jung
CEO, Chromo Tek

Microcoat



Custom Development: Development of diagnostic assays, test components and new test formats to market-ready kits. Immunological assays, molecular assays, sample and Matrix preparation protocols Contract manufacturing: Diagnostik kit and component manufacturing Service. Standard kit formats comprise ELISA, ELISpot, bead-based formats, lateral-flow kits. Production, modification and conjugation of antibodies and recombinant proteins, customized solid Phase coating, filling, freeze-drying, kit-assembly, ISO 9001 and 13485 Laboratory Services: Bioanalytics, companion diagnostics and platform development support. Biomarker Services, PK/PD, immunogenicity, sample measurement, endotoxin and pyrogen testing, Assay validation, method and System benchmarking, GLP, GC(L)P, cGMP. www.microcoat.de

Leukocare



LEUKOCARE provides proprietary formulation technologies and related development services for stabilization and protection of biologics LEUKOCARE technologies are employed in collaborations with partners in the field of vaccines, therapeutic proteins, and biologic device combination products. LEUKOCARE provides development services based on fee for service during implementation of its technologies.

LEUKOCARE technologies provide manifold benefits:

- Improved shelf-life / stability / quality
- Terminal sterilization of biologics
- Significant production cost savings

www.leukocare.com



www.bio-m.org/database

Upcoming Bio^M Events



The FORUM focuses on changes in medicine and offers a platform for the exchange between disciplines, researchers and users.



The BioEntrepreneurship Summit brings together all relevant stakeholders of the bioentrepreneurial and health tech ecosystem.

Save the Date 2020



BIO-Europe 26 – 28 October 2020, Munich
Europe's Largest Life Science Partnering Event to be held in Bavaria's capital!



Contact

Bio^M Biotech Cluster Development GmbH
Am Klopferspitz 19a
82152 Martinsried, Munich, Germany

 www.bio-m.org
 +49 (0) 89 89 96 790
 info@bio-m.org

Follow us on:   

Cluster Information



Dr. Georg Kääh
Kaeab@bio-m.org

International Affairs



Dr. Stephanie Wehnelt
Wehnelt@bio-m.org

Founders & Investors



Christina Enke-Stolle, Enke-Stolle@bio-m.org,
Angelika Leppert, Leppert@bio-m.org
Dr. Petra Burgstaller, Burgstaller@bio-m.org